Etravirine as a Switching Option for Patients with HIV RNA Suppression: A Review of Recent Trials

by Mark Nelson, Andrew Hill, Yvon van Delft, Christiane Moecklinghoff
Published 2014-01-01

Efficacy of Once Daily Darunavir/Ritonavir in PI-Naïve, NNRTI-Experienced Patients in the ODIN Trial

by Anna Maria Geretti, Mathe Moeketsi, Ralph Demasi, Yvon van Delft, Perry Mohammed
Published 2015-01-01

No difference in the rate of change in telomere length or telomerase activity in HIV-infected patients after three years of darunavir/ritonavir with and without nucleoside analogue...

by Ajantha Solomon, Surekha Tennakoon, Edwin Leeansyah, Jose Arribas, Andrew Hill, Yvon Van Delft, Christiane Moecklinghoff, Sharon R Lewin
Published 2014-01-01

Switching at Low HIV-1 RNA into Fixed Dose Combinations: TDF/FTC/RPV is non-inferior to TDF/FTC/EFV in first-line suppressed patients living with HIV

by Paula Munderi, Edwin Were, Anchalee Avihingsanon, Pascale A.M Mbida, Lerato Mohapi, Samba B. Moussa, Marjolein Jansen, Ceyhun Bicer, Perry Mohammed, Yvon van Delft
Published 2019-07-01